Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.
Avi Gadoth, Yael Paran, Yair Mina et al.
✦ AI-curated · Sources linked
Case in brief
This report details five patients with relapsed and refractory multiple myeloma who developed progressive multifocal leukoencephalopathy (PML following treatment with bispecific antibodies. All patients exhibited significant immune compromise, with clinical symptoms including dysarthria, ataxia, cognitive decline, and focal weakness. Diagnosis of PML was confirmed through PCR for JC virus in cerebrospinal fluid or brain biopsy. The cases highlight the need for vigilance in monitoring neurological symptoms in patients receiving bispecific antibody therapy.
Diagnostic / clinical pearl
Clinicians should be aware that progressive multifocal leukoencephalopathy can occur in patients receiving bispecific antibodies for multiple myeloma, even after limited prior therapies.
Why it matters
The occurrence of PML in this context underscores the importance of early recognition and evaluation of new neurological symptoms in patients undergoing bispecific antibody therapy.